About YZYBIO
A biotechnology company dedicated to developing BsAb-based therapies to treat
cancer or cancer-associated complications and age-related ophthalmologic diseases
Company Overview
Wuhan YZY Biopharma Co., Ltd.

Wuhan YZY Biopharma Co., Ltd. is a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer or cancer-associated complications,cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The mission is to discover and develop innovative drugs for healthier lives of patients.

 

Founded in 2010, YZYBIO has persisted in inhouse innovation, laid out and cultivated the field of bispecific antibodies, and developedfourinnovativeplatforms,including the self-developed YBODY® platform, Check-BODY platform and Nano-YBODY platform, and UVAX® platform developed in collaboration with WIV. The company has designed and developed a pipeline of seven clinical-stage drug candidates.

  • 4
    Innovative Platforms
  • 80 %
    R&D Employees
  • 78
    Patents and patent applications
    (of which 33 have been issued, and 45 applications are pending)
Leadership Team
Chairman of the Board & Chief Executive Officer
Zhou Pengfei
Zhou PengfeiChairman of the Board & Chief Executive Officer

Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively.He also got a Doctor of Philosophy from McMaster University in November 2005.

Dr. Zhou has over 33 years of experience in the healthcare and pharmaceutical industries, he worked for a number of leading enterprise, including Schering-Plough Corporation, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.

Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology as well as a visiting professor at Central South University.

Vice president of the manufacturing center
Yang Bin
Yang BinVice president of the manufacturing center

Dr. Yang Bin currently serves as the vice president of the manufacturing center of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).

Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.

Supervisor, Senior Director of the R&D Center
Zhang Jing
Zhang JingSupervisor, Senior Director of the R&D Center

Zhang Jing has served as a Supervisor since February 2018. Mr. Zhang joined the Group in January 2011 and successively served as a senior research assistant in the R&D center of the Company, a senior manager of the cell line development department of the Company and a director of the R&D center of the Company. In May 2023, he was promoted as the senior director of the R&D center of the Company. He is responsible for overseeing our operations and financial activities as well as leading the R&D center.

Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics of the Chinese Academy of Science (中国科学院生物物理研究所) from August 2008 to December 2010. Mr. Zhang has also served as a supervisor of Wuhan Huiyou Juyou Enterprise Management Co., Ltd. since June 2022.

Mr. Zhang received a bachelor's degree in biotechnology from the College of Life Sciences, Wuhan University (武汉大学) , and a master's degree in biochemistry and molecular biology from the Graduate School of Chinese Academy of Sciences (中国科学院研究生院) .

Senior Director of the Clinical Department
Dr. Huang Shaoyi
Dr. Huang ShaoyiSenior Director of the Clinical Department

Dr. Huang Shaoyi, currently serves as the senior director of the clinical department, who is responsible for the academic support of the Company's clinical projects and developing policies and management processes related to clinical research.

Dr. Huang has extensive experience in clinical research and product development. He served as the deputy director of the medical oncology department of Wuhan YZY Medical Science and Technology Co., Ltd. (武汉友芝友医疗科技股份有限公司) from March 2014 to July 2020, where he was responsible for R&D and clinical work.

He obtained a bachelor's degree in biotechnology in June 2001 and a master's degree in microbiology in December 2004 from Wuhan University (武汉大学), respectively. In August 2013, he obtained a doctorate in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center.

  • Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively.He also got a Doctor of Philosophy from McMaster University in November 2005.

    Dr. Zhou has over 33 years of experience in the healthcare and pharmaceutical industries, he worked for a number of leading enterprise, including Schering-Plough Corporation, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.

    Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology as well as a visiting professor at Central South University.

  • Dr. Yang Bin currently serves as the vice president of the manufacturing center of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).

    Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.

  • Zhang Jing has served as a Supervisor since February 2018. Mr. Zhang joined the Group in January 2011 and successively served as a senior research assistant in the R&D center of the Company, a senior manager of the cell line development department of the Company and a director of the R&D center of the Company. In May 2023, he was promoted as the senior director of the R&D center of the Company. He is responsible for overseeing our operations and financial activities as well as leading the R&D center.

    Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics of the Chinese Academy of Science (中国科学院生物物理研究所) from August 2008 to December 2010. Mr. Zhang has also served as a supervisor of Wuhan Huiyou Juyou Enterprise Management Co., Ltd. since June 2022.

    Mr. Zhang received a bachelor's degree in biotechnology from the College of Life Sciences, Wuhan University (武汉大学) , and a master's degree in biochemistry and molecular biology from the Graduate School of Chinese Academy of Sciences (中国科学院研究生院) .

  • Dr. Huang Shaoyi, currently serves as the senior director of the clinical department, who is responsible for the academic support of the Company's clinical projects and developing policies and management processes related to clinical research.

    Dr. Huang has extensive experience in clinical research and product development. He served as the deputy director of the medical oncology department of Wuhan YZY Medical Science and Technology Co., Ltd. (武汉友芝友医疗科技股份有限公司) from March 2014 to July 2020, where he was responsible for R&D and clinical work.

    He obtained a bachelor's degree in biotechnology in June 2001 and a master's degree in microbiology in December 2004 from Wuhan University (武汉大学), respectively. In August 2013, he obtained a doctorate in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center.

Milestones
2010
July

The predecessor of the Company, Wuhan YZY Biopharma Limited Company was established.

The initiation of BsAb platform development

2012
May
Established a GMP-compliant quality system
November

The initiation of M802 R&D

The filing of the PCT patent application “Bispecific antibody” for the protection of the YBODY® platform

2013
July
The initiation of M701 R&D
December
The determination of molecule structure of M802 and M701
2014
June
Novel Bispecific Antibody Drugs for the Treatment of Tumors Development Project (“新型肿瘤治疗性双特异性抗体药物开发课题”) selected for the Major Science and Technology Special Project for “Significant New Drugs Development” (“重大新药创制”科技重大专项) under the Twelfth Five-year Plan.
2015
September
M701 selected for the Major Science and Technology Special Project for “Significant New Drugs Development” (“重大新药创制”科技重大专项) under the Twelfth Five-year Plan.
2016
April
M802 became the first BsAb to file IND application in China.
August
Completed Series Pre-A Financing(1) and raised an aggregate amount of approximately RMB50 million.
2017
February

Patent protection for our YBODY® platform in U.S. expanded to cover 35 targets.

M701 became the second BsAb to file IND application in China.

September
Obtained NMPA IND approval for the clinical investigation of M802 in China, which is China’s first IND approval for self- developed BsAb.
2018
February

M701 received China’s second IND approval for self-developed bispecific antibody.

March 2018 The establishment of the Check-BODY platform

March
The establishment of the Check-BODY platform
April
Completed Series A Financing(1) and raised an aggregate amount of approximately RMB157.2 million.
December

Patent issued for the protection of M802 in China.

Patent issued for the protection of our YBODY® platform in CD3 and HER2 targets in U.S.

The establishment of the Nano-YBODY platform

2019
July
PCT patent application for the protection of our Check-BODY Platform was filed.
August
Obtained FDA IND approval for the clinical investigation of M802 in U.S.
October
Obtained FDA IND approval for the clinical investigation of M701 in U.S.
2020
February
The establishment of the UVAX® platform
August
Obtained FDA IND approval for the clinical investigation of Y150 in U.S.
2021
January

Completed Series B Financing(1) and raised an aggregate amount of approximately RMB168.7 million.

Obtained NMPA IND approval for our clinical investigation of Y150 in rrMM in China.

Obtained FDA IND approval for our clinical investigation of Y101D for solid tumors in U.S.

February
Completed Series B+ Financing(1) and raised an aggregate amount of approximately RMB20 million.
May
Obtained NMPA IND approval for our clinical investigation of Y101D in metastatic or locally advanced solid tumors in China.
August
Completed Series B++ Financing(1) and raised an aggregate amount of approximately RMB73.5 million.
December

Obtained NMPA IND approval for our clinical investigation of Y2019 in China

Initiated a Phase II clinical trial for M701 monotherapy in combination with systematic treatment for MA in patients with EpCAM-positive carcinomas in China.


2022
January

The Company was converted into a joint stock limited company with its name changed to “Wuhan YZY Biopharma Co., Ltd.(武汉友芝友生物制药股份有限公司)

July

Obtained IND approval for a Phase Ib/II clinical trial of M701 for the treatment of MPE in China.

Entered into asset transfer agreement with CMS Vision for Y400.

October
Completed Series C Financing(1) and raised an aggregate amount of approximately RMB200 million.
December

Obtained the IND approval for a Phase Ib/II clinical trial of Y101D in combination with gemcitabine and albumin paclitaxel as the first-line treatment for pancreatic cancer patients in China

Obtained IND approval for a Phase Ib/II clinical trial of Y101D in combination with bevacizumab in treating HCC and other advanced solid tumors in China

2023
April

Obtained IND approval for Y332 for metastatic or locally advanced solid tumors

Obtained IND approval for Y400 for wAMD and DME

2010
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Contact Us
  • Phone:
    027-82668988
  • E-Mail:
    info@yzybio.com
  • Postcode:
    430075
  • Address:
    Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
  • Fax:
    027-68788819
  • Business Development Contact:
    BD@yzybio.com